Predictive value of pre-procedural autoantibodies against M-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation by unknown
Zou et al. Journal of Translational Medicine 2013, 11:7
http://www.translational-medicine.com/content/11/1/7RESEARCH Open AccessPredictive value of pre-procedural autoantibodies
against M2-muscarinic acetylcholine receptor for
recurrence of atrial fibrillation one year after
radiofrequency catheter ablation
Changhong Zou†, Zhiyong Zhang†, Wenmin Zhao†, Guang Li†, Guiling Ma, Xinchun Yang, Jianjun Zhang*
and Lin Zhang*Abstract
Background: Increasing evidences have suggested that autoantibodies against muscarinic-2 acetylcholine receptor
(anti-M2-R) may play an important role in the development of atrial fibrillation (AF). Predictive value of
pre-procedural anti-M2-R for the recurrence of AF after radiofrequency catheter ablation is still unclear.
Methods: Totally 76 AF patients with preserved left ventricular systolic function were prospectively enrolled and
subjected to ablation after the detection of serum anti-M2-R by enzyme linked immunosorbent assay. These
patients were given follow-up examination for one year after ablation. Risk estimation for the recurrence of AF was
performed using the univariate and multivariate logistic regression.
Results: In AF group, serum anti-M2-R was significantly higher than that in the control group in terms of frequency
(40.8% versus 11.7%; p < 0.001) and titer (1:116 versus 1:29; p < 0.001). Compared with paroxysmal AF patients,
persistent AF patients had higher frequency (57.6% versus 27.9%; p = 0.009) and titer (1:132 versus 1:94; p = 0.012)
for autoantibodies. During one-year follow-up examination after ablation, the recurrence of AF was observed in 25
(32.9%) patients. Multivariate analysis showed that pre-procedural serum anti-M2-R was an independent predictor
for the recurrence of AF at the time point of 12 months after ablation (odds ratio: 4.701; 95% confidence interval:
1.590-13.894; p = 0.005).
Conclusions: In AF patients, the frequency and titer of serum anti-M2-R were significantly higher than those in the
control group with sinus rhythm. Pre-procedural serum anti-M2-R was an independent predictor for the recurrence
of AF one year after radiofrequency catheter ablation.
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RecurrenceBackground
Atrial fibrillation (AF) is one of the most common
arrhythmias in clinical setting, accounting for approxi-
mately one-third of hospitalizations for cardiac rhythm
disturbances [1]. AF is associated with the reduced exer-
cise capacity, degraded life quality, increased death rate,
stroke and other thromboembolic events as well as left* Correspondence: linzhangpeking@hotmail.com; zmn0359@vip.sina.com
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reproduction in any medium, provided the orventricular dysfunction [2]. To date, the underlying
mechanism of AF is not fully understood, emerging evi-
dences have indicated that autoimmunity may play an
important role in the development of AF [3].
M2 muscarinic receptor belongs to the family of cardiac
G-protein-coupled receptors. Circulating autoantibodies
against the second extracellular loop of M2-muscarinic
acetylcholine receptors (anti-M2-R) have been detected
in a large number of cardiovascular diseases such as
idiopathic dilated cardiomyopathy and chronic Chagas’s
heart disease characterized by heart failure [4,5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disorders including idiopathic atrial fibrillation and
sinus node dysfunction and ventricular arrhythmias
[6,7], suggesting that anti-M2-R is not only involved in
heart failure but also in arrhythmia. Anti-M2-R has re-
cently been reported as the strongest independent pre-
dictor for the development of AF in patients with
idiopathic dilated cardiomyopathy and patients with
Graves’ hyperthyroidism [6,8].
Over the past decades, radiofrequency catheter abla-
tion (RFCA) has evolved rapidly and become one of the
most effective methods for AF treatments so that it has
been used in many major hospitals all over the world, al-
though the recurrence rate of AF remains high [9]. Since
AF is a heterogeneous disease, the identification of
patients at high risk for the recurrence of AF by simple
and objective parameters may be helpful in tailoring
therapeutic strategies. Age, AF history, left ventricular
dysfunction, left atrial dilation and increased plasma
N-terminal pro-brain natriuretic peptide (NT-proBNP)
level have been associated with an elevated recurrence
rate of AF [10,11].
Therefore, the purposes of this study are to determine
whether serum anti-M2-R can increase in patients with
AF and preserved left ventricular systolic function, and
to assess the predictive value of pre-procedural serum




During the period from October 2009 to October 2010,
a total of 76 patients with paroxysmal (n = 43) or per-
sistent (n = 33) AF and preserved left ventricular systolic
function (left ventricular ejection fraction, LVEF > 60%),
who scheduled for RFCA in the heart center of Beijing
Chao-Yang Hospital, were prospectively enrolled. The
definition and classification was described in the guide-
lines for AF [2]. Exclusion criteria were intra-cardiac
thrombi especially in left atrium and left atrial append-
age, LVEF < 50%, renal insufficiency (serum creatinine ≥
176.8 μmol/L), a history of congenital heart disease,
rheumatic valvular heart disease, idiopathic cardiomyop-
athy, hyperthyroidism or other autoimmune diseases.
Patients with contraindication to anticoagulation or al-
lergy to iodide were also excluded from this study.
Meanwhile, totally 77 patients presented for primary
hypertension or coronary artery disease or just for med-
ical checkup during the same period with sinus rhythm,
LVEF > 60%, and age within 5 years in comparison with
AF patients were selected as the control group. Base-
line clinical characteristics were collected and plasma
NT-proBNP level was measured in all subjects. Trans-
thoracic echocardiography was used to evaluate leftatrial diameter and left ventricular function. Trans-
esophageal echocardiography should be performed to
confirm that there was no thrombus in the left atrium
or left atrial appendage. The study was complied with
the Declaration of Helsinki and was approved by the
Ethics Committee of Beijing Chao-Yang Hospital. All
subjects were provided the written informed consent
before study.Study protocol
Treatment with antiarrhythmic drugs of all patients was
discontinued for three days before the procedure; amiodar-
one was withdrawn at least 6 weeks before hospitalization.
Oral anticoagulation drugs were replaced by subcutaneous
low molecular weight heparin for at least 24 hours. Blood
samples were collected before RFCA and centrifuged at
3000 rpm for 10 minutes. The anti-M2-R was measured
with enzyme linked immunosorbent assay (ELISA), as
described by Fu [4].
All 76 patients with AF were subjected to circumferen-
tial ablation of pulmonary vein (CAPV) by applying radio-
frequency energy at the conditions with environmental
temperature of 43°C and limited power of 43 watts.
Guided by 3D electro-anatomical mapping systems such
as CARTO, continuous circumferential lesions that
encircled the right and left pulmonary vein ostia were per-
formed during sinus rhythm or AF. The end point of
CAPV was the elimination or dissociation of pulmonary
venous potentials throughout the ostial circumference. If
AF persisted or recurred during paced rhythm after
CAPV, additional substrate modification, for example, an
additional linear ablation of the left atrium “roof” line, or
“mitral isthmus” line may be required and the end point
of linear ablation was documented as bi-directional con-
duction block around linear ablation lesions.Follow-up examination
An echocardiogram was performed immediately after
the procedure to exclude the presence of pericardial ef-
fusion. All patients were subjected to hospital electrocar-
diogram telemetry monitoring for 72 hours. After
hospital discharge, all of the enrolled patients with AF
were scheduled for repeated visits in an outpatient clinic
at 1, 2, 3, 6 and 12 months after the ablation. At each
visit, patients were provided with cardiological examin-
ation and intensive questioning for arrhythmia-related
symptoms (palpations, chest discomfort, fatigue and diz-
ziness) at the heart center and a 12-lead electrocardio-
gram was also performed. Moreover, a 24-hour Holter
recording was conducted in 3, 6 and 12 months for all
of the patients. The recurrence of AF was defined as any
symptomatic or detected episodes of AF, atrial flutter
and atrial tachycardia longer than 30 seconds beyond
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arrhythmic drugs [9].
Statistical methods
Continuous data were expressed as Mean ± SD and cat-
egorical data were expressed as percentages. For group
comparisons, the Student’s t test for continuous vari-
ables and the chi-square test or Fisher’s exact test for
categorical variables were used. Association between
serum anti-M2-R level and the echocardio-graphic or
clinical indexes was evaluated by Spearman’s correl-
ation. Risk estimation was performed using univariate
and multivariate logistic regression model with the pres-
ence of recurrence of AF as dependent variable. All tests
were 2-tailed, and a significant difference was consid-
ered at the p < 0.05. Statistical analysis was performed




The clinical profiles of the study population were sum-
marized in Table 1. Compared to patients with sinus
rhythm, AF patients had larger left atrial diameter (39.86
± 5.35 mm vs. 35.33 ± 5.86 mm; p < 0.001) and higher
NT-proBNP level (213.85 ± 85.76 pg/mL versus 113.42 ±
31.15 pg/mL; p < 0.001). Demographic characteristics and
underlying diseases were similar between two groups.
Echocardiographic data including left ventricular end-
diastolic dimension (LVEDD), left ventricular end-systolic
dimension (LVESD) and LVEF did not reveal a significant
difference between two groups.
Autoantibody screening
Anti-M2-R was detected in 40.8% (31 of 76) of AF
patients, whereas that of 11.7% (9 of 77) in patients with
sinus rhythm (p < 0.001). Moreover, in positive cases,Table 1 Clinical profiles of the study population
Variables Sinus rhythm (n
Age (years) 65.68 ± 9.2
Gender (male) 36 (46.8%)
Hypertension (%) 36 (36.8%)
Diabetes mellitus (%) 14 (18.2%)
Coronary artery disease (%) 8 (10.4%)
Left atrial diameter (mm) 35.33 ± 5.8
Left ventricular end-diastolic diameter (mm) 45.34 ± 5.1
Left ventricular end-systolic diameter (mm) 27.55 ± 3.3
Left ventricular ejection fraction (%) 69.13 ± 4.9
NT-proBNP (pg/ml) 113.42 ± 30.
Data were expressed as numbers (%), Mean ± SD.
Abbreviations: NT-proBNP = N-terminal pro-brain natriuretic peptide.autoantibody titer (geometric mean) in AF patients was
significantly higher than that in patients with sinus
rhythm (1:116 versus 1:29; p < 0.001), as shown in
Figure 1. Subgroup analysis showed a significant differ-
ence in the frequency of anti-M2-R (57.6% versus 27.9%;
p = 0.009) and autoantibody titer (1:132 versus 1:94;
p = 0.012) between persistent and paroxysmal AF patients.
Ablation outcome
The end points of pulmonary vein disconnection or
elimination in all 76 patients with AF after CAPV were
achieved. Totally, 17 of 33 patients with persistent AF
(51.5%) and 9 of 43 patients with paroxysmal AF (20.9%)
were subjected to additional linear ablation. As for the
population in the present study, no patient was sub-
jected to repeated ablation.
Follow-up outcome
During one-year follow-up examination after the abla-
tion, the recurrence of AF was observed in 25 (32.9%)
patients. The baseline characteristics of two groups with
and without recurrent AF were listed in Table 2. No
statistical difference in age, gender, body mass index,
smoking, comorbidity (hypertension, diabetes mellitus
and coronary artery disease), medications and renal
function between both groups was observed. The echo-
cardiographic data including LVEDD, LVESD and LVEF
were also similar between both groups at baseline. Fur-
thermore, there is no significant difference in the abla-
tion protocol between two groups as well.
Patients with the recurrence of AF, however, had
more persistent AF (76.0% versus. 27.5%; p < 0.001),
larger left atrial diameter (44.9 ± 2.1mm versus 39.0 ±
3.5mm; p < 0.001), higher plasma NT-proBNP level
(347.80 ± 35.80 pg/mL versus 204.50 ± 56.35 pg/mL;
p = 0.012) when compared to patients without AF re-
currence. No significant difference in AF duration was= 77) Atrial fibrillation (n = 76) p value





6 39.86 ± 5.35 < 0.001
0 46.42 ± 3.92 0.270
2 28.04 ± 3.26 0.359
7 69.17 ± 5.98 0.979
15 213.85 ± 85.76 < 0.001
Figure 1 Difference in anti-M2-R between atrial fibrillation and
sinus rhythm patients. The frequency of anti-M2-R in AF patients
was 40.8%, which was significantly higher than that of 11.7% in
patients with sinus rhythm (A) (P < 0.001). The geometric mean titer
in AF patients was also significantly higher than that in patients with
sinus rhythm (B) (1:116 versus 1:29; P < 0.001).
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patients without AF recurrence (60 ± 15 months versus
24 ± 5 months; p = 0.090).
As for the autoantibodies, not only the frequency of
anti-M2-R (72.0% versus 25.5%; p < 0.001), but also the
titer of anti-M2-R (1:153 versus 1:80; p = 0.002) revealed
a significant difference between the patients with and
without AF recurrence, as shown in Figure 2.
Determinant of serum anti-M2-R level
The titer of serum anti-M2-R was highly correlated with
left atrial diameter (R = 0.490; p < 0.001) and plasma
NT-proBNP level (R= 0.502; p < 0.001). However, age,
body mass index, renal function, AF duration and
LVEDD, LVESD as well as LVEF were not correlated
with serum anti-M2-R level (p > 0.05).
Univariate and multivariate analysis of AF recurrence
Univariate analysis for AF recurrence during one-year
follow-up period was shown in Table 3. The variables
such as left atrial diameter, pre-procedural plasma NT-proBNP level and serum anti-M2-R level (both frequency
and titer) were significantly associated with AF recur-
rence at the time point of one year after RFCA including
persistent AF. In the multivariate logistic regression,
adjusted by persistent AF, left atrial diameter and pre-
procedural plasma NT-proBNP level, not only pre-
procedural titer of serum anti-M2-R (odds ratio: 2.339;
95% confidence interval: 1.509-3.626; p < 0.001) but also
the presence of anti-M2-R (odds ratio: 4.701; 95% confi-
dence interval: 1.590-13.894; p = 0.005) was an inde-




By using a synthetic peptide corresponding to the se-
quence of the second extracellular loop in human M2
receptor, we have detected anti-M2-R with ELISA and
demonstrated that the frequency and titer of serum
anti-M2-R in patients with AF and preserved left ven-
tricular systolic function were significantly higher than
those in the patients with sinus rhythm. Both fre-
quency and titer of serum anti-M2-R were associated
with the left atrial diameter and plasma NT-proBNP
level. The pre-procedural level of serum anti-M2-R
was an independent predictor of AF recurrence at
one year after RFCA. This study suggested the serum
anti-M2-R could be used as an integrating marker for
various risk factors of AF, and as an incremental pre-
dictive marker for the recurrence of AF after RFCA.
To date, this is the first report in which pre-
procedural serum anti-M2-R level was used to predict
the recurrence of AF at one year after RFCA.
Detection of serum anti-M2-R
Many studies have shown that circulating anti-M2-R
can be frequently identified in different cardiovascular
conditions such as idiopathic dilated cardiomyopathy,
chronic Chagas’s heart disease, and various arrhythmic
disorders, as well as in healthy individuals [11]. We
have found that the frequency of anti-M2-R in
patients with AF and preserved left ventricular sys-
tolic function was 40.8%, which was moderately
higher than 23.1% in idiopathic AF reported by Baba
et al. [6]. Furthermore, the titer of serum anti-M2-R
is significantly higher in patients with AF than that in
the patients with sinus rhythm.
Role of serum anti-M2-R in the development of AF
The underlying mechanism of AF is still not fully
understood. Over the past decades, multiple-circuit
reentry and focal electrical triggers are the major
conceptual models of AF [9]. AF is associated with
the reduced potential duration and effective refractory
Table 2 Characteristics of patients with and without atrial fibrillation recurrence after ablation
Variables No recurrence (n = 51) AF recurrence (n = 25) p value
Age (years) 65 ± 9 66 ± 8 0.728
Gender (male) 26 (51.0%) 13 (52.0%) 0.933
Body mass index (kg/m2) 25.74 ± 3.46 26.13 ± 3.65 0.710
Smoking (%) 21 (41.2%) 7 (28.0%) 0.263
Persistent atrial fibrillation (%) 14 (27.5%) 19 (76.0%) < 0.001
Duration of atrial fibrillation (months) 24 ± 5 60 ± 15 0.090
Comorbidity
Hypertension (%) 26 (51.0%) 11 (44.0%) 0.567
Diabetes mellitus (%) 13 (25.5%) 9 (36.0%) 0.343
Coronary artery disease (%) 5 (9.8%) 4 (16.0%) 0.432
Medications
Statins 22 (43.1%) 12 (48.0%) 0.689
ACEI/ARB 40 (78.4%) 18 (72.0%) 0.536
Renal function
Blood urea nitrogen (mmol/L) 5.67 ± 1.60 5.43 ± 1.87 0.630
Creatinine (μmol/L) 77.58 ± 16.81 79.75 ± 8.85 0.526
Creatinine clearance (mL/min) 83.12 ± 28.23 79.06 ± 22.86 0.616
Echocardiographic data
Left atrial diameter (mm) 39.0 ± 3.5 44.9 ± 2.1 < 0.001
Left ventricular end-diastolic diameter (mm) 46.3 ± 3.9 46.9 ± 4.2 0.593
Left ventricular end-systolic diameter (mm) 28.0 ± 3.1 27.5 ± 2.1 0.411
Left ventricular ejection fraction (%) 69.0 ± 5.8 70.0 ± 3.5 0.354
NT-proBNP (pg/ml) 204.50 ± 56.35 347.80 ± 35.80 < 0.001
Ablation protocol (persistent AF) n=14 n=19
CAPV+additional linear ablation 8 (57.1%) 9 (47.4%) 0.728
CAPV+LA "roof" line 8 (57.1%) 9 (47.4%) 0.728
CAPV+LA "mitral isthmus" line 8 (57.1%) 9 (47.4%) 0.728
Ablation protocol (paroxysmal AF) n=37 n=6
CAPV+additional linear ablation 7 (18.9%) 2 (33.3%) 0.589
CAPV+LA "roof" line 7 (18.9%) 2 (33.3%) 0.589
CAPV+LA "mitral isthmus" line 5 (13.5%) 0 -
Data were expressed as numbers (%), Mean ± SD.
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, NT-proBNP = N-terminal pro-brain natriuretic peptide,
CAPV=circumferential ablation of pulmonary vein, LA=left atrium.
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acetylcholine-gated potassium channel IK-Ach [12].
These electrophysiological changes (a process called
“electrical remodeling”) promote the initiation and
maintenance of AF [13]. Besides, many studies have
also found that AF patients often have a larger left
atrial diameter and greater atrial fibrosis (a process
called “structure remodeling”), which partly attributes
to the induction and persistence of AF through de-
creasing the atrial conduction velocity and prolonging
intra-atrial activation time [14]. Autonomic nervous
system plays an important role in the development ofAF. Vagal stimulation shortens atrial action potential
duration and effective refractory period, and increases
the dispersion of atrial effective refractory period,
which can create an arrhythmogenic substrate for the
initiation and perpetuation of AF [15]. Serum anti-
M2-R can specifically recognize and bind to amino
acids 169–193 of the second extracellular loop in the
M2-muscarinic acetylcholine receptor. Functional
studies have demonstrated that these autoantibodies
are not only able to bind to target receptors in the
myocardium, but also to induce receptor-mediated
biological responses as partial agonists [15]. Stavrakis
Figure 2 Difference in anti-M2-R between patients with and
without recurrence. The frequency of anti-M2-R in the patients
with recurrent AF was significantly higher than that without
recurrence (A) (72.0% versus 25.5%; P < 0.001). The geometric mean
titer of anti-M2-R in the recurrent patients was also higher than that
in the patients without recurrence (B) (1:153 versus 1:80; P = 0.002).
Table 3 Univariate and multivariate analysis for atrial fibrillat
Variables Univariate analysis
OR 95% CI
Age (years) 1.009 0.951-1.071
Gender (male) 0.935 0.337-2.579
Persistent AF 3.794 1.350-10.659
Duration of AF (months) 1.005 0.998-1.012
Left atrial diameter (mm) 1.108 1.002-1.225





Abbreviations: OR=odds ratio, CI=confidence interval, AF=atrial fibrillation, LVEF=lef
peptide, anti-M2-R = autoantibody against muscarinic-2 acetylcholine receptor.
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hyperthyroidism, the presence of anti-M2-R can facili-
tate shortening of action potential duration and local
autonomic nerve stimulation-induced firing in pul-
monary veins. By studying the effect of anti-M2-R on
rabbit atria in vivo, Hong CM et al. [16] have demon-
strated that anti-M2-R can induce atrial electrophysi-
ology remodeling, atrial fibrosis and exert a tonic
activation of M2 receptor signal transduction. These
results suggest the presence of anti-M2-R may partici-
pate in the induction and perpetuation of AF.
Our present study find both the frequency and the
titer of serum anti-M2-R are positively correlated with
left atrial diameter. Moreover, AF patients with anti-
M2-R are more prone to AF recurrence after ablation
than the patients with autoantibody deficiency, which
further confirmed the hypothesis that anti-M2-R may
play an important role in the initiation and persist-
ence of AF.
Predictive value of anti-M2-R for the recurrence of AF
after ablation
Since AF is a heterogeneous disease, the identification
of patients at high risk for the recurrence of AF using
simple and objective parameters may be helpful in
tailoring the therapeutic strategies. According to pre-
vious studies, old age, long AF history, persistent AF,
left ventricular dysfunction (systolic and/or diastolic
dysfunction), left atrial dilation and increased plasma
NT-proBNP level have been associated with an ele-
vated recurrence rate of AF [10,11].
In the present study, the AF patients with preserved
left ventricular systolic function have been used as
subjects to conduct univariate analysis and the results
have demonstrated that the variables such as enlarged
left atrial diameter and increased pre-proceduralion recurrence after ablation
Multivariate analysis








<0.001 2.339 1.509-3.626 <0.001
0.002 4.701 1.590-13.894 0.005
t ventricular ejection fraction, NT-proBNP = N-terminal pro-brain natriuretic
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with the recurrence of AF at one year after RFCA in-
cluding persistent AF, which is in good agreement
with several previous studies [10,11,17]. Besides, both
the frequency and the geometric mean titer of anti-
M2-R reveal significant difference between the
patients with AF recurrence and the patients with
sinus rhythm restoration. Multivariate logistic regres-
sion analysis indicated that pre-procedural titer and
frequency of serum anti-M2-R were independent pre-
dictors for recurrence of AF at one year after RFCA.
Study limitations
Several limitations of our study must be acknowl-
edged. We did not measure the levels of anti-M2-R
after ablation, consequently being not able to demon-
strate the superiority of baseline anti-M2-R as a pre-
dictor over a change in its levels. In addition, we did
not perform echocardiography at one year after abla-
tion, which could have been used to assess the effect
of successful ablation on the left atrial size. The sub-
group analysis, although it is of interest, is limited by
the relatively small number of study population.
Finally, in this study, the AF recurrence might have
been underestimated because only intermittent 24 h
Holter recording and interviews could results in mis-
recording of asymptomatic AF recurrence during the
clinical follow-up.
Conclusions
In patients with AF and preserved left ventricular sys-
tolic function, the frequency and titer of serum anti-M2-
R are higher than those in the patients with sinus
rhythm. Meanwhile, serum anti-M2-R level is associated
the left atrial diameters and plasma NT-proBNP level.
The pre-procedural level of anti-M2-R is an independent
predictor for the recurrence of AF at one year after
ablation.
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